Cytosorbents (CTSO) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTSO shares.
View CTSO analyst ratings or view top-rated stocks.

1 brokers have issued 12-month target prices for Cytosorbents' stock. Their CTSO share price forecasts range from $5.50 to $5.50. On average, they anticipate the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 78.6% from the stock's current price.
View analysts price targets for CTSO or view top-rated stocks among Wall Street analysts.

Cytosorbents' stock was trading at $1.55 at the beginning of 2023. Since then, CTSO stock has increased by 98.7% and is now trading at $3.08.
View the best growth stocks for 2023 here.

Cytosorbents saw a increase in short interest in May. As of May 15th, there was short interest totaling 800,600 shares, an increase of 19.7% from the April 30th total of 669,100 shares. Based on an average daily trading volume, of 72,600 shares, the days-to-cover ratio is currently 11.0 days. Currently, 2.1% of the shares of the stock are short sold.
View Cytosorbents' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our CTSO earnings forecast.

Cytosorbents Co. (NASDAQ:CTSO) issued its earnings results on Thursday, March, 9th. The medical research company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.16. The medical research company earned $9.39 million during the quarter, compared to analysts' expectations of $9.40 million. Cytosorbents had a negative net margin of 87.94% and a negative trailing twelve-month return on equity of 82.56%.

11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

Cytosorbents' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Skylands Capital LLC (6.27%), Granahan Investment Management LLC (3.57%), Sargent Investment Group LLC (2.77%), CM Management LLC (1.02%), Jacob Asset Management of New York LLC (0.54%) and Dimensional Fund Advisors LP (0.20%). Insiders that own company stock include Al Kraus, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi.
View institutional ownership trends.

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTSO stock can currently be purchased for approximately $3.08.

Cytosorbents (NASDAQ:CTSO) has a market capitalization of $135.38 million and generates $29.35 million in revenue each year. The medical research company earns $-32,810,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

The company employs 221 workers across the globe.

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.cytosorbents.com. The medical research company can be reached via phone at (732) 329-8885, via email at avogel@cytosorbents.com, or via fax at 732-329-8650.